MW 464.1 Da, Purity >98%. Selective, cell-permeable p300/CBP histone acetyltranserase inhibitor (IC50 = 5 μM). Antitumor agent. Active in vitro.
E1A binding protein p300, E1A-associated protein p300, EP300: E1A binding protein p300, EP300_HUMAN, Histone acetyltransferase p300, KAT3B, RSTS2, p300 HAT
MW 464.1 Da, Purity >98%. Selective, cell-permeable p300/CBP histone acetyltranserase inhibitor (IC50 = 5 μM). Antitumor agent. Active in vitro.
Soluble in DMSO to 100 mM.
Soluble in ethanol to 25mM.
Selective, cell-permeable p300/CBP histone acetyltranserase inhibitor (IC50 = 5 μM). Antitumor agent. Active in vitro.
KAT3B also known as p300 is a histone acetyltransferase with a molecular weight of approximately 300 kDa. Known for its ability to acetylate histone and non-histone proteins p300 modulates gene expression by altering chromatin structure. The protein is ubiquitously expressed across various tissues impacting numerous cellular processes by its mechanical functions of modifying chromatin.
KAT3B/p300 influences multiple cellular activities like cell growth differentiation and apoptosis. It functions as a transcriptional coactivator and integrates various signaling pathways into the cell's gene expression program. p300 often forms complexes with other transcription factors enhancing or repressing their activity based on the cellular context. By modifying transcription factors it plays an essential role in controlling cell fate decisions.
P300 participates in the regulation of significant cellular processes including the Wnt signaling pathway and the p53 pathway. In the Wnt signaling pathway p300 acts alongside beta-catenin to regulate gene expression while in the p53 pathway it acetylates the p53 protein influencing the cell’s response to DNA damage. These pathways highlight p300's interaction with important proteins such as CBP (CREB-binding protein) which shares a similar functional repertoire and works synergistically in gene regulation.
P300 is implicated in cancers and congenital disorders. In cancer aberrant regulation or mutation of p300 can lead to uncontrolled cell proliferation and tumor growth; p300 inhibitors like C646 are researched for their therapeutic potential. Additionally Rubinstein-Taybi syndrome a congenital disorder results from mutations in the p300 gene showcasing p300’s importance in developmental processes. The interplay of p300 with proteins such as CBP is also relevant in these conditions where disrupted interactions may lead to disease manifestation.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2D chemical structure image of ab144556, Histone Acetyltransferase Inhibitor II, p300/CBP HAT inhibitor
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com